LGND Stock Analysis: Buy, Sell, or Hold?
LGND - Ligand Pharmaceuticals Inc.
$300.97
-8.28 (-2.68%)
▼
5d:
-5.78%
30d:
+18.23%
90d:
+41.01%
HOLD
LOW Confidence
Analysis Updated: Jul 14, 2026 12:00 AM ET
Earnings: Aug 06, 2026
22d
Get Alerted When LGND Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: LGND trades at premium valuation expecting 6.3% growth. Hold existing positions but don't chase. Wait for better entry.
📊 HOLD: LGND trades at premium valuation expecting 6.3% growth. Hold existing positions but don't chase. Wait for better entry.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$500.84
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$310.98
3.2% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 22.4x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: LGND is currently trading at $300.97, which is considered slightly high relative to its 30-day fair value range of $255.29 to $315.05. From a valuation perspective, the stock is trading at a premium (Forward PE: 26.9) compared to its historical average (22.4). At these levels, the market is pricing in 6.3% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, LGND is in a strong uptrend. The price is currently testing key support at $302.03. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, LGND is in a strong uptrend. The price is currently testing key support at $302.03. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$255.29 -
$315.05
Company Quality Score
60/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
68.1%
Protect Your Profits
Holding LGND? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($297.50)
- NEUTRAL: PE elevated vs history but 6.3% growth expectation is conservative given 103% recent growth
- CAUTION: Recommendation downgraded due to -5.8% 5-day decline
Trading Range Analysis
30-Day Trading Range
$255.29 -
$315.05
Current vs Trading Range
SLIGHTLY HIGH
Expected Move (7 Days)
±$18.35
(6.1%)
Support & Resistance Levels
Support Level
$302.03
Resistance Level
$326.63
Current Trend
Strong Uptrend
Technical data as of
Jul 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
26.93
Wall Street Target
$297.50
(-3.8%)
Revenue Growth (YoY)
14.1%
Earnings Growth (YoY)
103.2%
Profit Margin
56.0%
Valuation Premium vs History
+6.3% premium
PE vs Historical
26.9 vs 22.4
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+6.3%
(market-implied from PE analysis)
1-Year Target
$328.73
(+6%)
2-Year Target
$349.44
(+13%)
3-Year Target
$371.46
(+20%)
3-Yr Target (if PE normalizes)
(PE: 27→22)
PE COMPRESSION
$308.93
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 26.9, Growth: 25.4%)
$609.61
(+97%)
Base:
(SPY PE: 21.8, Growth: 25.4%)
$492.96
(+59%)
Bear:
(PE: 18.5, Growth: 25.4%)
$419.01
(+36%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (41x PE), but valuation improves significantly next year (27x PE) as earnings recover.
Trailing PE: 41.18 | Current EPS (TTM): $7.68
Bull Case
$520.06
(+68%)
Analyst growth 49.5%, PE expands to 45.3
Base Case
$472.78
(+53%)
Market implied 49.5%, PE stable at 41.2
Bear Case
$215.04
(-31%)
Severe decline -20.0%, PE contracts to 35.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: July 14, 2026 4:57 PM ET
Data refreshes hourly during market hours. Next update: 5:57 PM
Data refreshes hourly during market hours. Next update: 5:57 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LGND showing a specific setup today?
Insider Activity (6 Months)
1
Buys
9
Sells
Net
INSIDERS SELLING
Recent Transactions
John W Kozarich
SELL
467 shares
2026-04-01
Andrew Reardon
SELL
5000 shares
2026-04-01
Stephen L Sabba
SELL
1000 shares
2026-03-23
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 65 BUY |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1051 | 52 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$277 | 58 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$85 | 50 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 55 HOLD |
Advanced LGND Option Strategies
Professional options setups generated by AI based on today's LGND price and gamma walls.
